Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia
- 2.8k Downloads
Antipsychotic drugs have been used to treat patients with schizophrenia and other psychotic disorders. Long-acting injectable antipsychotic drugs are useful for improving medication compliance with a better therapeutic option to treat patients who lack insight or adhere poorly to oral medication. Several long-acting injectable antipsychotic drugs are clinically available. Haloperidol decanoate and fluphenazine decanoate are first-generation depot drugs, but the use of these medicines has declined since the advent of second-generation depot agents, such as long-acting risperidone, paliperidone palmitate, and olanzapine pamoate. The second-generation depot drugs are better tolerated and have fewer adverse neurological side effects. Long-acting injectable risperidone, the first depot formulation of an atypical antipsychotic drug, was prepared by encapsulating risperidone into biodegradable microspheres. Paliperidone palmitate is an aqueous suspension of nanocrystal molecules, and olanzapine pamoate is a microcrystalline salt of olanzapine and pamoic acid suspended in aqueous solution. This review summarizes the characteristics and recent research of formulations of each long-acting injectable antipsychotic drug.
KeywordsAntipsychotic drugs Long-acting formulation Olanzapine pamoate Paliperidone palmitate Risperidone Schizophrenia
This research was financially supported by the Ministry of Knowledge Economy (MKE) and Korea Institute for Advancement in Technology (KIAT) through the Research and Development for Regional Industry. This research was also supported by the leading industry and equipments of the ChungCheong Leading Industry Office of the Korean Ministry of Knowledge.
- Janssen, P.A., C.J. Niemegeers, F. Awouters, K.H. Schellekens, A.A. Megens, and T.F. Meert. 1988. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. Journal of Pharmacology and Experimental Therapeutics 244: 685–693.PubMedGoogle Scholar
- Kramer, M., R. Litman, D. Hough, R. Lane, P. Lim, Y. Liu, and M. Eerdekens. 2010. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. International Journal of Neuropsychopharmacology 13: 635–647.PubMedCrossRefGoogle Scholar
- Leucht, S., T.R. Barnes, W. Kissling, R.R. Engel, C. Correll, and J.M. Kane. 2003. Relapse prevention in schizophrenia with new-generation antipsychotics: A systematic review and exploratory metaanalysis of randomized, controlled trials. American Journal of Psychiatry 160: 1209–1222.PubMedCrossRefGoogle Scholar
- Sedky, K., R. Nazir, J.P. Lindenmayer, and S. Lippman. 2010. Paliperidone palmitate: Once monthly treatment option for schizophrenia. Current Psychiatry Online 9: 48–50.Google Scholar
- Selmin, F., P. Blasi, and P. P. Deluca. 2012. Accelerated polymer biodegradation of risperidone poly(d,l-lactide-co-glycolide) microspheres. AAPS Pharm Sci Tech 13: 1465–1472.Google Scholar
- Su, Z.X., Y.N. Shi, L.S. Teng, X. Li, L.X. Wang, Q.F. Meng, L.R. Teng, and Y.X. Li. 2011. Biodegradable poly(d,l-lactide-co-glycolide) (PLGA) microspheres for sustained release of risperidone: Zero-order release formulation. Pharmaceutical Development and Technology 16: 377–384.PubMedCrossRefGoogle Scholar
- Zuardi, A.W., A.C. Giampietro, and E.R. Grassi. 1983. Double-blind comparison between two forms of haloperidol: An oral preparation and a new depot decanoate in the maintenance of schizophrenic inpatients. Current Therapeutic Research 34: 253–261.Google Scholar